Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Loviscol - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Loviscol

Approved

STANDARD

Loviscol

Interphil Laboratories, Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 022de21c31cf81b8
Company: Interphil Laboratories, Inc.
Type: Standard

Approval Details

Approval Id: 022de21c31cf81b8
Drug Approval Philippines Name: Loviscol
Product Name: Loviscol
Registration Number: DRHR-1265
Brand Name: Loviscol
Generic Name: Carbocisteine
Dosage Form: Syrup (Oral Drops)
Dosage Strength: 50 mg/mL
Manufacturer: Interphil Laboratories, Inc.
Trader: GlaxoSmithKline Consumer Healthcare Philippines, Inc.
Issuance Date: 26 March 2021
Expiry Date: 07 March 2026
Pharmacologic Category: Mucolytic
Classification: Household Remedy (HR)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

022de21c31cf81b8

Type

Standard

Back to Philippines FDA Approvals